Lei Tang1, Lu Deng1, Harrison X Bai2, James Sun2, Natalie Neale3, Jing Wu4, Yinyan Wang5, Ken Chang6, Raymond Y Huang7, Paul J Zhang8, Xuejun Li9, Bo Xiao4, Ya Cao10, Yongguang Tao11, Li Yang12. 1. Department of Neurology, The Second Xiangya Hospital, Central South University, No. 139 Middle Renmin Road, Changsha, 410011, Hunan, People's Republic of China. 2. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA. 3. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. 4. Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. 5. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 10050, People's Republic of China. 6. Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, 02129, USA. 7. Department of Radiology, Brigham and Women's Hospital, Boston, MA, 02115, USA. 8. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA. 9. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. 10. Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, 410078, Hunan, People's Republic of China. 11. Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, 410078, Hunan, People's Republic of China. taoyong@csu.edu.cn. 12. Department of Neurology, The Second Xiangya Hospital, Central South University, No. 139 Middle Renmin Road, Changsha, 410011, Hunan, People's Republic of China. yangli762@csu.edu.cn.
Abstract
BACKGROUND: Lower-grade gliomas (LGGs, defined as WHO grades II and III) with 1p19q codeletion have increased chemosensitivity when compared to LGGs without 1p19q codeletion, but the mechanism is currently unknown. METHODS: RNAseq data from 515 LGG patients in the Cancer Genome Atlas (TCGA) were analyzed to compare the effect of expression of the 9 DNA repair genes located on chromosome arms 1p and 19q on progression free survival (PFS) and overall survival (OS) between patients who received chemotherapy and those who did not. Chemosensitivity of cells with DNA repair genes knocked down was tested using MTS cell proliferation assay in HS683 cell line and U251 cell line. RESULTS: The expression of 9 DNA repair genes on 1p and 19q was significantly lower in 1p19q-codeleted tumors (n = 175) than in tumors without the codeletion (n = 337) (p < 0.001). In LGG patients who received chemotherapy, lower expression of LIG1, POLD1, PNKP, RAD54L and MUTYH was associated with longer PFS and OS. This difference between chemotherapy and non-chemotherapy groups in the association of gene expression with survival was not observed in non-DNA repair genes located on chromosome arms 1p and 19q. MTS assays showed that knockdown of DNA repair genes LIG1, POLD1, PNKP, RAD54L and MUTYH significantly inhibited recovery in response to temozolomide when compared with control group (p < 0.001). CONCLUSIONS: Our results suggest that reduced expression of DNA repair genes on chromosome arms 1p and 19q may account for the increased chemosensitivity of LGGs with 1p19q codeletion.
BACKGROUND: Lower-grade gliomas (LGGs, defined as WHO grades II and III) with 1p19q codeletion have increased chemosensitivity when compared to LGGs without 1p19q codeletion, but the mechanism is currently unknown. METHODS: RNAseq data from 515 LGG patients in the Cancer Genome Atlas (TCGA) were analyzed to compare the effect of expression of the 9 DNA repair genes located on chromosome arms 1p and 19q on progression free survival (PFS) and overall survival (OS) between patients who received chemotherapy and those who did not. Chemosensitivity of cells with DNA repair genes knocked down was tested using MTS cell proliferation assay in HS683 cell line and U251 cell line. RESULTS: The expression of 9 DNA repair genes on 1p and 19q was significantly lower in 1p19q-codeleted tumors (n = 175) than in tumors without the codeletion (n = 337) (p < 0.001). In LGG patients who received chemotherapy, lower expression of LIG1, POLD1, PNKP, RAD54L and MUTYH was associated with longer PFS and OS. This difference between chemotherapy and non-chemotherapy groups in the association of gene expression with survival was not observed in non-DNA repair genes located on chromosome arms 1p and 19q. MTS assays showed that knockdown of DNA repair genes LIG1, POLD1, PNKP, RAD54L and MUTYH significantly inhibited recovery in response to temozolomide when compared with control group (p < 0.001). CONCLUSIONS: Our results suggest that reduced expression of DNA repair genes on chromosome arms 1p and 19q may account for the increased chemosensitivity of LGGs with 1p19q codeletion.
Entities:
Keywords:
1p19q codeletion; Chemosensitivity; DNA repair genes; Lower-grade gliomas
Authors: S El Ghamrasni; R Cardoso; L Li; K K N Guturi; V A Bjerregaard; Y Liu; S Venkatesan; M P Hande; J T Henderson; O Sanchez; I D Hickson; A Hakem; R Hakem Journal: Oncogene Date: 2016-02-15 Impact factor: 9.867
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: José L McFaline-Figueroa; Christian J Braun; Monica Stanciu; Zachary D Nagel; Patrizia Mazzucato; Dewakar Sangaraju; Edvinas Cerniauskas; Kelly Barford; Amanda Vargas; Yimin Chen; Natalia Tretyakova; Jacqueline A Lees; Michael T Hemann; Forest M White; Leona D Samson Journal: Cancer Res Date: 2015-05-29 Impact factor: 12.701
Authors: Thomas Viel; Parisa Monfared; Sonja Schelhaas; Inga B Fricke; Michael T Kuhlmann; Cornel Fraefel; Andreas H Jacobs Journal: Mol Ther Date: 2013-01-15 Impact factor: 11.454
Authors: Susan C Short; Silvia Giampieri; Mulugeta Worku; Marisa Alcaide-German; George Sioftanos; Sara Bourne; Ka Ian Lio; Maya Shaked-Rabi; Christine Martindale Journal: Neuro Oncol Date: 2011-03-01 Impact factor: 12.300
Authors: Sandra Hocke; Yang Guo; Albert Job; Michael Orth; Andreas Ziesch; Kirsten Lauber; Enrico N De Toni; Thomas M Gress; Andreas Herbst; Burkhard Göke; Eike Gallmeier Journal: Oncotarget Date: 2016-02-09
Authors: Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Bryan W Day; Brett W Stringer; Paul A Tooney Journal: Cells Date: 2022-04-04 Impact factor: 6.600
Authors: Hao Zhou; Ken Chang; Harrison X Bai; Bo Xiao; Chang Su; Wenya Linda Bi; Paul J Zhang; Joeky T Senders; Martin Vallières; Vasileios K Kavouridis; Alessandro Boaro; Omar Arnaout; Li Yang; Raymond Y Huang Journal: J Neurooncol Date: 2019-01-19 Impact factor: 4.506